HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) fell 4.5% during mid-day trading on Tuesday . The company traded as low as $15.01 and last traded at $15.10. 16,653 shares changed hands during trading, a decline of 82% from the average session volume of 90,882 shares. The stock had previously closed at $15.81.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
View Our Latest Research Report on HUTCHMED
HUTCHMED Stock Down 4.0 %
The stock has a fifty day moving average of $16.59 and a two-hundred day moving average of $17.85. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.
Hedge Funds Weigh In On HUTCHMED
A number of large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in HUTCHMED in the third quarter valued at about $35,000. Jane Street Group LLC grew its position in shares of HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after buying an additional 49,366 shares during the period. State Street Corp grew its position in shares of HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after buying an additional 3,078 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of HUTCHMED during the third quarter worth approximately $421,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock valued at $952,000 after buying an additional 24,245 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
